The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Fidelity Select Biotechnology FBIOX
- NAV / 1-Day Return 18.10 / −1.36 %
- Total Assets 4.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.660%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.81%
- Turnover 52%
USD | NAV as of May 10, 2024 | 1-Day Return as of May 10, 2024, 10:12 PM GMT+0
Morningstar’s Analysis FBIOX
Will FBIOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 13.84 | 679.1 Mil | Healthcare |
Amgen Inc | 7.38 | 362.0 Mil | Healthcare |
Krystal Biotech Inc | 6.94 | 340.3 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 3.75 | 184.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.15 | 154.5 Mil | Healthcare |
Gilead Sciences Inc | 2.23 | 109.6 Mil | Healthcare |
Ascendis Pharma A/S ADR | 2.03 | 99.7 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 1.99 | 97.7 Mil | Healthcare |
Arcellx Inc | 1.80 | 88.3 Mil | Healthcare |
Biohaven Ltd | 1.68 | 82.2 Mil | Healthcare |